secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001999480-24-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q2 2024 net loss $16.0M; cash $193.6M; Phase 2b MDD topline due Oct 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents, and restricted cash of $193.6M as of June 30, 2024; expected to fund operations into 2027.
- Net loss of $16.0M for Q2 2024 vs $8.7M in Q2 2023; R&D expenses rose to $13.2M from $7.1M.
- Completed enrollment of 301 patients in Phase 2b MDD study of ALTO-100; topline data expected in October 2024.
- Initiated Phase 2 studies: ALTO-101 in schizophrenia CIAS, ALTO-203 in MDD with anhedonia, ALTO-100 in bipolar depression.
- Received $11.7M Wellcome Trust award for ALTO-100 in bipolar depression; added COO Michael Hanley.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000033/0001999480-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000033/alto-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001999480-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer